Proteopathies are a large and diverse group of human diseases that are caused by protein misfolding. Wellknown examples of proteopathies are Alzheimer's and Parkinson's disease, which are both linked to amyloid fibril formation. In this issue of Chemistry & Biology, Castellano et al. (2015) describe the way to harness the power of a protein from baker's yeast, Hsp104, to disaggregate the fibrils.
Amyloid fibrils are highly ordered b sheet-rich protein aggregates associated with a large number of neurodegenerative diseases but also with normal biological functions such as storage of peptide hormones in secretory granules (Greenwald and Riek, 2010) . The identification of amyloid-forming endogenous peptides in semen and their implications in HIV infectivity further demonstrate the diverse functions of amyloid fibrils (Mü nch et al., 2007) . Despite an increased understanding of amyloid assembly both in vitro and in vivo, it has proven difficult to find effective therapeutics for diseases caused by amyloid proteins. In most neurodegenerative diseases, the progression and severity of the disease depends on the accumulation of several types of misfolded species (oligomers, protofibrils and fibrils) that form during the assembly of amyloids. Because these species have variable conformations and structural details that are not well understood, it has been challenging to develop therapeutics targeting all the conformers simultaneously. Hence, there has been a great effort to generate therapeutics targeting the common structural features in these misfolded aggregates. One approach has been to engineer conformational antibodies that recognize oligomers, protofibrils, and mature fibrils to block toxicity and fibril assembly (Haupt and Fä ndrich, 2014; Kayed et al., 2003) .
Protein misfolding and aggregation is a common feature of cell physiology. To prevent the damaging effects of protein misfolding, cells have evolved various endogenous mechanisms such as chaperone pathways to ensure proper and rapid folding of nascent polypeptide chains and degradation of improperly folded proteins (Brandvold and Morimoto, 2015) . The paper by Castellano and coworkers presents a novel approach in the use of a modified, yeast-specific chaperone Hsp104 as a possible therapeutic to remodel amyloids in semen and reduce HIV infectivity and transmission (Castellano et al., 2015) . Hsp104 is a disaggregase involved in the recovery after stress-induced protein aggregation in S. cerevisiae and the only cellular component known to remodel amyloid fibrils (Glover and Lindquist, 1998) . Hsp104 has been shown to have diverse substrate specificity and can disaggregate toxic oligomers, a pre-fibrillar state capable of self-templating, as well as amyloid fibrils formed from a large number of proteins (Shorter and Lindquist, 2004) . The fact that its specificity toward different amyloids can be modulated by minor changes in the amino acid sequence makes it a very promising candidate for designing amyloid therapeutics (Jackrel and Shorter, 2015) .
Castellano et al. describe in vitro Hsp104 remodeling and aggregate clustering of amyloid fibrils from proteolytic fragments of prostatic acid phosphatase (PAP) and semenogelin 1 (SEM1). PAP248-286 (SEVI) fibrils incubated with Hsp104 were remodeled into non-amyloid aggregates with reduced binding to the amyloid binding dye Thioflavin-T (ThT). The transformation of cross b sheet-rich structures to amorphous aggregates was also visualized by transmission electron microscopy (TEM). The remodeling does not generate increased levels of monomers and the resulting non-amyloid aggregated material had lost its seeding capacity. Next, the authors explore the remodeling activity of an enhanced variant of the disaggregase Hsp104 A503V that has previously been shown to remodel TDP-43 and a-synuclein protein aggregates implicated in frontotemporal lobar dementia (FTLD), amyotrophic lateral Figure 1 ). In addition, Hsp104 was found to promote the formation of larger aggregates of seminal amyloids in an ATP-independent manner. The dual activity of Hsp104 to either remodel fibrils into large amorphous aggregates with less cross b sheet-rich structure or cluster fibrils into larger aggregates appeared to be fibril specific. Various shorter versions of the protein analyzed for remodel and clustering activity showed that amyloid remodeling requires Hsp104 to be in the active hexameric form as well as ATP hydrolysis whereas the backbone of Hsp104 is sufficient for the clustering of amyloid into larger aggregates. Further, the remodeled amorphous material was readily degraded by the bacterial peptidase, ClpP associated with HAP, a modified Hsp104 variant. A cell-based assay was used to evaluate the effect of various Hsp104 variants on seminal fibril remodeling, clustering, degradation and HIV infectivity. As expected, the remodeled material with less b sheet-rich protein aggregates had reduced HIV infectivity and treatment with the enhanced Hsp104 yielded the most significant reduction. Interestingly, fibrils that are not remodeled by Hsp104 but clustered together forming larger aggregates also show reduced HIV infectivity positively correlated with aggregation size.
How do we apply this information to design therapeutic molecules, specifically to treat amyloid diseases? The large size of the disaggregase and lack of prior knowledge about manufacturing and administering large protein complexes makes it difficult to consider Hsp104 as a therapeutic candidate against amyloids. Further, ensuring proper assembly of the active chaperone complex in the complex milieu of aggregating proteins and providing a constant supply of nucleotides would be challenging.
Alternatively, we suggest two more feasible strategies to design and develop therapeutic molecules against amyloids: grafting the substrate binding domain to therapeutic scaffolds and engineering amyloid-specific nanomachine disaggregators.
Hsp104 is a suitable candidate for grafting the substrate binding domain to therapeutic scaffolds because these studies show that Hsp104 is capable of binding a wide range of substrates in a sequence-independent or conformationdependent manner. A large fraction of the potentiated variants that bind unnatural substrates only show alterations in their ATPase activity and altered interdomain communication. Therefore, if the precise substrate-binding domain is identified, transferring this to an antibody or smaller more stable structure like the nanobody or single chain antibody (Perchiacca et al., 2012) could allow generation of new class of potent amyloid-specific conformational binders.
Hsp104 is also a suitable candidate for engineering amyloid-specific nanomachine disaggregators because it can both bind to a diverse group of misfolded structures and remodel them. To do this, Hsp104 uses the peristaltic mechanism of substrate threading facilitated by a sequential hydrolysis of ATP molecules and an associated re-arrangement of the different domains in the active hexamer. If this movement is replicated in a monomeric protein with 2 domains, one for binding substrates transiently and the other to induce conformational change in the substrate-bound complex, then it could be engineered to bind amyloid substrates and induce its remodeling. Hsp104 variants that fail to multimerize but retain substrate binding and ATPase activity (partial or complete) could be good scaffolds to begin with. Other molecules like the prolyl isomerases SlyD and FkpA or the TolA binding phage protein g3p could also function as good scaffolds (Schmidpeter and Schmid, 2015) . All these molecules trigger conformational changes in their domains by a cis-trans proline isomerization. This would also eliminate the need for ATP to fuel the conformational switch. Interestingly, the phage protein g3p binds a large number of amyloid proteins in a conformation-dependent manner with very high affinity (Krishnan et al., 2014) (Figure 2) .
S. cerevisiae harbors a large number of self-replicating protein aggregates. These aggregates act as heritable epigenetic elements that allow the fungi to survive in diverse and often harsh environmental conditions. The chaperone networks in these organisms have been evolved to maintain protein aggregates without causing any detrimental effects to the cells. With most traditional approaches to make therapeutic molecules against amyloids failing over the last two decades, we should probably realign our approach to select therapeutic molecules based on conformational binders like the metazoan Hsp104 that remodel amyloids without any toxic side effects. The substrate binding domain (SBD) and conformational change inducing domain (CID) work in tandem to bind and remodel fibers. SlyD, g3p, and FkpA are alternate scaffolds that can be engineered to bind and remodel aggregates.
